KR20120094469A - 면역원성 말라리아원충 포자소체 단백질 에피토프로 재조합 아데노바이러스의 변형 - Google Patents

면역원성 말라리아원충 포자소체 단백질 에피토프로 재조합 아데노바이러스의 변형 Download PDF

Info

Publication number
KR20120094469A
KR20120094469A KR1020127006889A KR20127006889A KR20120094469A KR 20120094469 A KR20120094469 A KR 20120094469A KR 1020127006889 A KR1020127006889 A KR 1020127006889A KR 20127006889 A KR20127006889 A KR 20127006889A KR 20120094469 A KR20120094469 A KR 20120094469A
Authority
KR
South Korea
Prior art keywords
asn
pro
gly
leu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127006889A
Other languages
English (en)
Korean (ko)
Inventor
타카유키 시라추치
모리야 추지
Original Assignee
더 락커펠러 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 락커펠러 유니버시티 filed Critical 더 락커펠러 유니버시티
Publication of KR20120094469A publication Critical patent/KR20120094469A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127006889A 2009-08-18 2010-08-18 면역원성 말라리아원충 포자소체 단백질 에피토프로 재조합 아데노바이러스의 변형 Ceased KR20120094469A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2009/054212 WO2011022002A1 (en) 2009-08-18 2009-08-18 Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
WOPCT/US2009/054212 2009-08-18

Publications (1)

Publication Number Publication Date
KR20120094469A true KR20120094469A (ko) 2012-08-24

Family

ID=43607237

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127006889A Ceased KR20120094469A (ko) 2009-08-18 2010-08-18 면역원성 말라리아원충 포자소체 단백질 에피토프로 재조합 아데노바이러스의 변형

Country Status (16)

Country Link
US (1) US20170348405A1 (enExample)
EP (2) EP3412306A3 (enExample)
JP (2) JP5947719B2 (enExample)
KR (1) KR20120094469A (enExample)
CN (2) CN105770880A (enExample)
BR (1) BR112012003808A2 (enExample)
CA (1) CA2769415A1 (enExample)
IL (1) IL217709A (enExample)
MX (1) MX339830B (enExample)
NZ (1) NZ598703A (enExample)
PH (1) PH12012500164A1 (enExample)
RU (1) RU2585228C2 (enExample)
SG (2) SG178476A1 (enExample)
UA (1) UA108081C2 (enExample)
WO (2) WO2011022002A1 (enExample)
ZA (1) ZA201201286B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210116712A (ko) * 2013-06-03 2021-09-27 브이엘피 테라퓨틱스 엘엘씨 말라리아 백신

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154199A1 (en) 2010-10-18 2012-11-15 The Government Of The United States, As Represented By The Secretary Of The Army Soluble recombinant plasmodium falciparum circumsporozoite protein
US20120244178A1 (en) * 2011-03-25 2012-09-27 Denise Doolan Plasmodium falciparum antigens
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
WO2017048689A1 (en) * 2015-09-16 2017-03-23 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
US10517938B2 (en) 2016-01-21 2019-12-31 Janssen Vaccines & Prevention B.V. Adenovirus based malaria vaccine encoding and displaying a malaria antigen
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN107841513B (zh) * 2016-09-18 2023-04-14 中国科学院上海巴斯德研究所 基于M2e表位的广谱型流感疫苗
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN108192876A (zh) * 2017-12-07 2018-06-22 东莞市第八人民医院 一种人3型腺病毒衣壳蛋白同时展示ca16双中和抗原表位疫苗候选株的制备方法和应用
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
WO2020221451A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies binding to plasmodium circumsporozoite protein and uses thereof
CN110687289B (zh) * 2019-10-17 2023-04-18 中国人民解放军陆军军医大学 Fgl2蛋白作为疟疾感染标志物的应用
GB201915905D0 (en) * 2019-11-01 2019-12-18 Spybiotech Ltd Viruses with modified capsid proteins
JP2021178021A (ja) * 2020-05-14 2021-11-18 株式会社三洋物産 遊技機
US20240240203A1 (en) * 2021-05-04 2024-07-18 SpyBiotech Limited Adenoviral vectors and vaccines thereof
CA3233100A1 (en) * 2021-09-23 2023-03-30 Sagittarius Bio, Inc. Adenoviruses and methods for using adenoviruses
CN120944926B (zh) * 2025-10-15 2026-01-30 华中科技大学同济医学院附属同济医院 衣壳表面展示超大片段抗原的重组腺病毒、构建方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066623A (en) * 1993-11-23 2000-05-23 The United States Of America As Represented By The Secretary Of The Navy Polynucleotide vaccine protective against malaria, methods of protection and vector for delivering polynucleotide vaccines
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
US8232255B2 (en) * 2002-10-23 2012-07-31 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
EP1573012B1 (en) * 2002-12-17 2011-11-30 Crucell Holland B.V. Recombinant viral-based malaria vaccines
CA2524499A1 (en) * 2003-05-14 2004-11-25 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Broadening adenovirus tropism
JP2005287309A (ja) * 2004-03-31 2005-10-20 Dnavec Research Inc 遺伝子導入を増強するための薬剤および方法
CN101072879B (zh) * 2004-10-13 2011-05-11 克鲁塞尔荷兰公司 改良的腺病毒载体及其应用
US8765146B2 (en) * 2005-08-31 2014-07-01 Genvec, Inc. Adenoviral vector-based malaria vaccines
US20100272753A1 (en) * 2006-10-26 2010-10-28 The Johns Hopkins University Recombinant Adenovirus Vaccines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210116712A (ko) * 2013-06-03 2021-09-27 브이엘피 테라퓨틱스 엘엘씨 말라리아 백신

Also Published As

Publication number Publication date
CA2769415A1 (en) 2011-02-24
CN103025349A (zh) 2013-04-03
SG10201404970PA (en) 2014-10-30
CN103025349B (zh) 2016-05-18
WO2011022002A1 (en) 2011-02-24
ZA201201286B (en) 2013-05-29
JP2013502221A (ja) 2013-01-24
HK1179508A1 (zh) 2013-10-04
UA108081C2 (uk) 2015-03-25
MX2012002131A (es) 2012-04-11
EP2467157A4 (en) 2014-01-22
IL217709A (en) 2016-05-31
PH12012500164A1 (en) 2022-03-09
SG178476A1 (en) 2012-03-29
IL217709A0 (en) 2012-03-29
AU2010286187A1 (en) 2012-02-16
EP3412306A2 (en) 2018-12-12
RU2585228C2 (ru) 2016-05-27
JP5947719B2 (ja) 2016-07-06
EP2467157A1 (en) 2012-06-27
RU2012110255A (ru) 2013-09-27
JP6293181B2 (ja) 2018-03-14
MX339830B (es) 2016-06-13
CN105770880A (zh) 2016-07-20
NZ598703A (en) 2014-04-30
JP2016146837A (ja) 2016-08-18
EP3412306A3 (en) 2019-01-02
BR112012003808A2 (pt) 2016-11-16
WO2011022522A1 (en) 2011-02-24
US20170348405A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
JP6293181B2 (ja) 免疫原性マラリア原虫周辺スポロゾイトタンパク質エピトープによる組換えアデノウイルスの改変
JP2013502221A5 (enExample)
US9555089B2 (en) Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
WO2012023995A1 (en) Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes
JP5222289B2 (ja) マラリア用ワクチン
JP6110347B2 (ja) 新規方法および組成物
US20140348791A1 (en) Modified adenoviral vectors and methods of treatment using same
JP2022101574A (ja) 組換えアデノウイルスおよびその使用
AU2003298361B2 (en) Recombinant viral-based malaria vaccines
AU2006284756B2 (en) Adenoviral vector-based malaria vaccines
ES2871907T3 (es) Portadores de vacuna de adenovirus de chimpancé
JP6177981B2 (ja) 迅速かつ持続的な免疫学的治療法
Bruder et al. Molecular vaccines for malaria
Palma et al. Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice
AU2010286187B2 (en) Modification of recombinant adenovirus with immunogenic Plasmodium circumsporozoite protein epitopes
HK1179508B (en) Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
ES2377964T3 (es) Vacunas contra la malaria basadas en virus recombinante

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120316

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150817

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160913

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170716

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160913

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170716

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170313

Comment text: Amendment to Specification, etc.

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180427

Patent event code: PE09021S01D

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20181204

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180427

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20171215

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20171013

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20170716

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170313

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20160913

X601 Decision of rejection after re-examination